Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors
YANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced the appointments of Mr. Xin Wang as Chief Executive Officer and director, Mr. Lianzhang Zhao as Chief Financial Officer...
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patent Epidemiological research shows that the incidence rate of DED...
Medical Metaverse Company, apoQlar, Receives FDA 510(k) Clearance for its Mixed Reality Surgical Planning Platform, VSI HoloMedicine®
HAMBURG, Germany, Dec. 5, 2022 /PRNewswire/ -- apoQlar, a German medical technology company, today announced it has received FDA 510(k) Class II clearance for VSI HoloMedicine®, a pioneering mixed reality software device enabling surgeons to plan complex procedures using the power of immersive 3D holographic technology. With this clearance, the USA becomes...
Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform
SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge...
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they...
The First IBCC Unveiled in Hainan
SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) in Hainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting. A patient-centered facility, the IBCC serves to improve inpatient experiences as well as medical service efficiency through a full-course management model. Gao Xinpu, Director of the Medical Administration Bureau of...
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)
ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today...
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals’ Seizure Detection Wearable Device at AES 2022
Poster session features a preliminary study result of potential seizure monitoring and detection for patients using SK Biopharmaceuticals' wearable device SK Biopharmaceuticals, Seoul National University Bundang Hospital plan to use Zero WiredTM to further pursue clinical research and develop it into an AI-based seizure detection medical device PANGYO, South Korea, Dec. 5, 2022...
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis (UC). This Phase II clinical study will evaluate the efficacy and safety of LNK01003...
Telix Announces Executive Leadership Appointments
MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valeix promoted to Group Chief Commercial Officer Richard Valeix, who has been in the role...
